
usd dec pm et
summari contract clinic research organ provid health care data
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
dec pm stock trade
technolog analyt solut ta
sale grew yoy larger
grew sale yoy driven healthi demand
outsourc clinic trial servic
biopharmaceut client segment
see notabl slowdown howev
sale grew yoy respect
sale growth year accompani
mix cost perform ytd gross
margin basi point yoy
sg expens ratio improv basi
point net effect yoy growth
adjust pre-tax incom even
faster per share basi roughli
spent share repurchas
adjust ep show robust growth
concern qualiti
earn ytd cash oper flat
yoy free cash flow drop yoy
declin free cash flow borrow
fund repurchas increas debt yoy
unsustain mean maintain
earn growth view
mix view iqvia thank share
buyback see ep growth yet
cost increas debt despit sustain
growth rd ta segment expect
revenu growth declin yoy
yoy due competit
remain skeptic on-going
strategi increas debt fund buyback
prior im health acquisit
annual ebita-to-interest coverag
sinc declin
thu think iqvia well posit
pursu -- trend investor like
becam accustom spree
bolt-on acquisit sinc start
moreov share look cheap base
forward price-to-earnings basi rel histor
averag limit ep benefit
buyback continu think manag
focu increas earn
speed clinic trial time client rather
financi maneuv
target price ep estim
close histor forward price-to-earnings averag
risk view includ lower biopharma
spend slowdown analyt due
risk assess account benefit
diversifi servic signific earn come
health care technolog analyt well
contract research commerci servic
drug compani expect industri
experi long-term demand growth increas
effici health care deliveri becom greater focu
develop nation advanc medicin
prolifer emerg market benefit
balanc view signific competit
face major advers impact stem
withdraw delay larg drug develop project
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc form octob merger quintil
transnat global contract research organ cro im health provid prescript
electron health record data combin compani integr cro health care
inform technolog servic provid
iqvia serv key health care organ decis maker world-wide span breadth life
scienc compani includ pharmaceut biotechnolog consum health medic devic
manufactur well health care distributor provid payer govern agenc policymak
research financi commun roughli revenu gener america
europ africa asia iqvia oper three busi segment research
develop solut rd revenu technolog analyt solut ta contract
rd provid servic expertis enabl biopharmaceut compani outsourc
develop process drug servic rang clinic trial design recruit
manag post-launch monitor segment typic contract biopharmaceut firm
outsourc portion spend complement in-hous oper rd
servic help client conduct monitor multi-sit clinic trial improv clinic trial data
manag decis make
ta provid client health care industri solut measur improv perform
softwar servic option broad rang health care custom real-world insight
help health care stakehold meet increas demand faster insight evid appli
digit technolog scientif expertis machin learn clinic data analyt consult
servic offer broad set strateg implement consult servic includ advanc
analyt commerci process outsourc servic inform offer provid
perform metric relat sale pharmaceut product prescrib trend medic treatment
promot activ across multipl channel includ retail hospit mail order
csm offer rang servic includ contract sale market focus improv
brand drug valu stage product life-cycle initi market entri brand near patent
expiri patient engag servic includ nurse-bas program directli engag
patient help improv diseas medic understand intervent
non-intervent support medic affair servic help biopharmaceut compani plan
transit clinic trial set commerci
competit cro industri several-hundr small limited-servic provid sever
medium-s firm full-servic compani global capabl research
develop solut segment compet global includ covanc inc drug develop
busi laboratori corpor america hold icon plc parexel intern
product develop inc syneo health among other technolog
analyt solut segment face numer competitor includ larg corpor certain
govern agenc corpor competitor ta includ optuminsight cogniz technolog
covanc parexel intern among other
corpor strategi iqv ta segment primarili result acquisit im health
financ issuanc billion worth new equiti share billion
assum debt deal primari driver iqv increas invest capit estim
billion end billion end think sharehold would
better without deal howev adjust pre-tax earn per share grew three-year
compound-annual-growth-rate materi under-perform broader health care sector follow
im health purchas spent billion smaller bolt-on
acquisit estim return invest capit among lowest global
sinc primarili result larg im health purchas
financi trend total revenu increas billion billion
repres three-year compound annual growth rate compound-annual-growth-rate period includ larg im
acquisit conduct stock issuanc im sharehold worth
billion assumpt billion assum debt reason think best gaug
oper perform past three year adjust pre-tax incom per share includ
capit cost sharehold dilut interest new debt well restructur cost
acquisit fee relat growth strategi also avoid incorpor posit impact tax
chang focus oper adjust pre-tax incom per share grown
three-year compound-annual-growth-rate also remain highli leverag follow acquisit
view adjust oper earn cover net interest expens
around im health acquisit
strategi share repurchas boost ep expect continu despit increas
leverag made share repurchas increas total share repurchas
first nine month expect share repurchas continu sinc
compani author remain howev buyback financ
debt remain skeptic strategi due neg impact indebted free cash
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc decemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow sharpli
rate achiev posit
earn growth view
healthi fund public medic research
demand growth emerg market expect
factor balanc slower
biopharmaceut spend growth
neg effect trade tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect mark
major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev
mani biopharmaceut firm look limit
spend growth off-set recent
revenu headwind patent expir
public scrutini high drug price larg
swath biopharma typic flow
lst firm suppli depart
research tool softwar contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
final recent escal trade tariff
neg impact lst earn
growth view expect
continu analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat escal tariff impos
 -china trade
soften demand -made
instrument china rais product
cost instrument maker limit
suppli chain flexibl end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
year-to-d septemb
 life scienc tool
servic rose broader
base index
five-year market price perform dec
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra lower recommend share inc
sell hold maintain target price ep
estim downgrad opinion howev think
futur growth justifi current premium valuat increas invest
capit last three year acquisit intend
improv competit posit think posit improv
howev estim organ sale growth yoy materi
lag revenu growth broader health care sector believ
technolog analyt segment lose market share organ growth
rate materi lag competitor optuminsight yoy also expect
grow total sale around materi lag growth expect
peer like iclr given forecast below-averag growth
current trade highest forward price-to-earnings industri expect share
under-perform broader market year ahead /colin scarola
pm et cfra maintain hold recommend share
inc rais target
ep estim -- histor forward price-to-earnings averag due strong
growth outlook segment ep vs
beat consensu keep ep estim
revenu grew yoy led growth organ technolog
 analyt sale growth organ
growth strong note
organ rate technolog analyt materi lag competitor like
optuminsight cogniz healthcar grew sale yoy
respect view indic segment may lose market
share execut well oper side lower sg yoy
materi improv adjust pre-tax margin
expect drive ep growth think
share alreadi near fair valu /colin scarola
analyst research note compani news
et cfra lift recommend share
sell hold rais target
ep estim close iqv histor forward price-to-earnings averag
maintain ep estim rais ep estim
ep estim see
revenu growth strong yoy expect
sustain around yoy believ healthi demand outsourc clinic
trial servic biopharmaceut client continu drive organ
growth rd segment also expect solid momentum ta busi
continu thank new custom win ep grow faster revenu
share buyback view cost higher debt remain
skeptic iqv on-going strategi increas debt fund buyback
leverag alreadi high net debt/ebitda stood septemb
neutral see clear posit reduct
et cfra maintain sell recommend share
inc lower target ep estim
-- histor forward price-to-earnings averag maintain
ep estim start ep vs beat
consensu total revenu grew yoy put pace
slowdown revenu growth despit worth
acquisit past year technolog analyt revenu
trend remain strong year year-to-d revenu yoy
research develop slow yoy growth last year
 growth continu materi lag peer like iclr view due
rel lack integr patient site network speed clinic
trial time underli profit also concern gross
profit flat yoy despit revenu growth given alreadi high leverag
valuat rel peer question recent increas debt fund
pm et cfra maintain sell recommend share
inc rais target price ep
estim line histor forward price-to-earnings averag ep
vs beat consensu rais ep estim
maintain revenu grew yoy led
strong growth yoy technolog analyt revenu
yoy segment seen signific
slowdown growth level howev gross margin
contract basi point yoy cost rise faster revenu
report non-gaap ep first half grew yoy cash
oper expand receiv day rais concern
qualiti earn view first half capital-expenditure also jump yoy drive
drop free cash flow think attract underli
busi believ near-record-high price-to-earnings valuat poor cash flow
et cfra maintain sell recommend share
inc lower target ep
estim histor forward price-to-earnings averag due outlook
slow sale growth ep vs beat consensu
maintain ep ep estim revenu grew yoy
slow growth full-year adjust pre-tax incom grew
yoy note receiv turnov drop yoy cash
oper fell yoy suggest us qualiti earn
worsen despit alreadi high leverag nearli
debt-to-ebita end debt ad
proce go share repurchas cash gener slow think
may turn debt buyback help meet ep guidanc
think practic sustain appar stretch payment
term custom base develop think may
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
